-
06:35:08 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

BLUE Stock News

09/16/22 11:51 PM
Nasdaq : BLUE
high short
bluebird bio Receives FDA Accelerated Approval for SKYSONA(R) Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)
bluebird bio, Inc. today announced the U.S. Food and Drug Administration has granted Accelerated Approval of SKYSONA (R), also known as eli-cel, to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy. "Children with CALD and their families have been at the heart of bluebird' s mission since the...
RHEA-AI
neutral
08/17/22 2:32 PM
Nasdaq : BLUE
high short
bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO(R), the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions
Following the FDA approval of ZYNTEGLO (R), also known as beti-cel, for the treatment of beta-thalassemia in adult and pediatric patients who require regular red blood cell transfusions, today bluebird bio released details of its U.S. commercial infrastructure to support rapid access to ZYNTEGLO, including an innovative, outcomes-based contract offering...
RHEA-AI
positive
08/17/22 2:03 PM
Nasdaq : BLUE
fda approvalhigh short
bluebird bio Announces FDA Approval of ZYNTEGLO(R), the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions
Data from the Cooley' s Anemia Foundation indicate that the median age of death of patients with transfusion-dependent beta- thalassemia in the U.S. who died during the last decade was just 37 years. bluebird estimates that there are approximately 1,300-1,500 individuals with transfusion-dependent beta-thalassemia in the U.S.. "The Cooley' s Anemia...
RHEA-AI
very positive
08/04/22 4:05 PM
Nasdaq : BLUE
earningshigh short
bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress
bluebird bio, Inc. today reported financial results and business highlights for the second quarter ended June 30, 2022, and shared recent operational progress. UNANIMOUS POSITIVE VOTE AT FDA ADVISORY COMMITTEE MEETING- On June 10, the U.S. Food and Drug Administration' s Cellular, Tissue, and Gene Therapies Advisory Committee voted that the benefits of...
RHEA-AI
positive
06/10/22 3:18 PM
Nasdaq : BLUE
high short
FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with beta-thalassemia Who Require Regular Red Blood Cell Transfusions
bluebird bio, Inc. today announced the outcome of the U.S. Food and Drug Administration' s Cellular, Tissue, and Gene Therapies Advisory Committee discussion of betibeglogene autotemcel for the treatment of people with beta-thalassemia who require regular red blood cell transfusions. "Despite advances in care, people living with the most severe form of...
RHEA-AI
neutral
06/09/22 6:14 PM
Nasdaq : BLUE
high short
FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy
bluebird bio, Inc. today announced the outcome of the U.S. Food and Drug Administration' s Cellular, Tissue, and Gene Therapies Advisory Committee discussion of elivaldogene autotemcel for the treatment of early active cerebral adrenoleukodystrophy in patients less than 18 years of age who do not have an available and willing human leukocyte antigen-...
RHEA-AI
neutral
06/07/22 8:36 AM
Nasdaq : BLUE
high short
bluebird bio Announces Posting of Briefing Documents for Upcoming FDA Advisory Committee Meeting
bluebird bio, Inc. today announced that the U.S. Food and Drug Administration posted briefing documents for the FDA Cellular, Tissue and Gene Therapies Advisory Committee Meeting to review elivaldogene autotemcel for early active cerebral adrenoleukodystrophy in patients without a matched sibling donor and betibeglogene autotemcel for the treatment...
RHEA-AI
neutral